Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis
-
摘要: 目的观察慢性乙型肝炎(CHB)和肝硬化患者经替比夫定抗病毒治疗3、6个月后血清可溶性红细胞补体受体1(s CR1)的变化,探讨替比夫定治疗对于s CR1水平的的影响。方法选择2013年1-6月在兰州军区兰州总医院安宁分院就诊的HBe Ag阳性CHB、肝硬化患者57例,给予替比夫定抗病毒治疗,于治疗前和治疗后3、6个月抽静脉血,采用ELISA法检测s CR1。组内比较采用配对t检验。两组间比较采用独立样本t检验。结果替比夫定抗病毒治疗后,全部患者在治疗3、6个月时s CR1与对应的基线水平相比差异有统计学意义(t值分别为4.864、6.238,P值均<0.05)。CHB患者和肝硬化患者s CR1水平在治疗3、6个月时与对应的基线相比差异均有统计学意义(t值分别为3.425、5.468、4.047、7.378,P值均<0.05)。CHB患者血清s CR1水平在基线、治疗3、6个月均较肝硬化患者低,但两组间各时间点相比差异均无统计学意义(P值均>0.05)。结论 HBe Ag阳性CHB、肝硬化患者经替比夫定抗病毒治疗后血清s CR1水平显著下降。Abstract: Objective To investigate the changes in serum soluble complement receptor type 1(s CR1) at 3 and 6 months after antiviral therapy with telbivudine in patients with chronic hepatitis B(CHB) or liver cirrhosis and the influence of telbivudine on serum s CR1 level.Methods A total of 57 patients with HBe Ag- positive CHB or liver cirrhosis were enrolled and given the antiviral therapy with telbivudine.Venous blood was collected before treatment and at 3 and 6 months after treatment,and enzyme- linked immunosorbent assay was used to measure serum s CR1 level.The paired t- test was used for comparison within one group.Results At 3 and 6 months after the antiviral treatment with telbivudine,the serum s CR1 level changed significantly compared with corresponding baseline values(t = 4.864 and 6.238,both P < 0.05).The patients with CHB or liver cirrhosis showed significant changes in the serum s CR1 level at 3 and 6 months after treatment compared with corresponding baseline values(t = 3.425,5.468,4.047,7.378 all P < 0.05).The patients with CHB had a lower serum s CR1 level at baseline and at 3 and 6 months after treatment than those with liver cirrhosis,but the serum s CR1 level at each time point showed no significant differences between the two groups(all P > 0.05).Conclusion In patients with HBe Ag- positive CHB or liver cirrhosis,serum s CR1 level is reduced significantly after antiviral therapy with telbivudine.
-
Key words:
- hepatitis B /
- chronic /
- liver cirrhosis /
- telbifvdine
-
[1]WEBSTER GJ,REIGNAT S,MAINI MK,et al.Incubationphase of acute hepatitis B in man:dynamic of cellularimmune mechanisms[J].Hepatology,2000,32(5):1117-1124. [2]RAPICETTA M,FERRARI C,LEVRERO M.Viral determinants and host immune responses in the pathogenesis of HBV infection[J].J Med Viro,2002,67(3):454-457. [3]TANNER MS.Mechanisms of liver injury relevant to pediatric hepatology[J].Crit Rev Clin Lab Sci,2002,39(1):1-61. [4]MAINI MK,BONI C,LEE CK,et al.The role of virus specific CD8(+)cells in liver damage and viral control during persisten the patitis B virus infection[J].J Exp Med,2000,191(8):1269-1280. [5]LIAW YF,GANE E,LEUNG N,et al.2 year GLOBE trial results:telbivudine is superior to lamivudine in patiants with chronic hepatitis B[J].Gstroenterology,2009,136(2):486-495. [6]HOU JL,YIN YK,XU D,et al.A PhaseⅢcomparative trial of telbivudine and lamivudine for treatment of chronic hepatitis B in Chinense patients:first year results[R].Shanghai-Hong Kong international Liver Congress,2006,180. [7]EVANS A,RIVA A,COOKSLEY H,et al.Programmed death 1 expression during antiviral treatment of chronic hepatitis B:Impact of hepatitis B e-antigen seroconversion[J].Hepatology,2008,48(3):759-769. [8]ZHANG MJ,ZHOU JJ,FU XL,et al.The effect of telbivudine on peripheral blood CD4+CD25+CD127lowT cells and CD8+CD25+Tcells and its clinical significance[J].Immunol J,2010,26(7):594-597.(in Chinese)张梦军,周吉军,傅晓岚,等.替比夫定对慢性乙型肝炎患者外周血细胞频率的影响及临床意义[J].免疫学杂志,2010,26(7):594-597. [9]ZHU B,ZHANG P,WANG TB,et al.Measurement of Th1/Th2cytokine levels in chronic hepatitis B during telbivudine therapy[J].J Clin Hepatol,2009,25(6):415-417.(in Chinese)朱斌,张平,王天宝,等.替比夫定治疗慢性乙肝血清Th1/Th2亚群细胞因子的水平变化[J].临床肝胆病杂志,2009,25(6):415-417. [10]LUO LS,ZHANG JW,ZHOU JL,et al.Distribution and significance of spots mutation of complement receptor type 1 gene of erythrocytes in patients with E antigen positive[J].J Pract Med,2011,27(15):2838-2840.(in Chinese)罗丽莎,张继万,周建丽,等.HBe Ag阳性慢性乙肝患者红细胞补体受体Ⅰ型分子基因点突变的分布及意义[J].实用医学杂志,2011,27(15):2838-2840. [11]LI XB,YANG WD.Advances in clinical research on immune function of erythrocytes in patients with liver diseases[J].Lab Med Clin,2008,5(2):104-106.(in Chinese)李续斌,杨文东.肝脏疾病患者红细胞免疫功能临床研究进展[J].检验医学与临床,2008,5(2):104-106. [12]DONG GF,LIU DY,WANG JB,et al.The changes and the significance of soluble complement receptor type 1 in serum of patients with hepatitis B gravis[J].Chin J Hepatol,2004,12(2):108-109.(in Chinese)董格峰,刘典勇,王晶波,等.重型肝炎患者血清可溶性补体受体Ⅰ型的变化及临床意义[J].中华肝脏病杂志,2004,12(2):108-109. [13]LUO LS,ZHANG JW,ZHOU JL,et el.Relationship between the red cell nature immune adhesion function and the concentrations of the soluble complement receptor type 1 in patients with e antigen positive[J].Lab Med Clin,2012,9(9):1069-1071.(in Chinese)罗丽莎,张继万,周建丽,等.慢性乙型肝炎患者红细胞天然免疫黏附功能与血清s CR1变化的相关性研究[J].检验医学与临床,2012,9(9):1069-1071. [14] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ. [15]WANG H,WANG XF,YANG LH,et al.Changes and clinical significance of solub1e complement receptor I(s CR 1)of patients with hepatitis[J].Chin J Heal Lab Tech,2007,17(10):1757-1758.(in Chinese)王晗,王雪飞,杨丽华,等.不同肝病患者血清s CR1浓度变化及临床意义研究[J].中国卫生检验杂志,2007,17(10):1757-1758.
本文二维码
计量
- 文章访问数: 1887
- HTML全文浏览量: 9
- PDF下载量: 447
- 被引次数: 0